Creative Biogene Creative Biogene
Inquiry
Pages
Products
  1. Home
  2. Services
  3. Target-based Drug Discovery Service
  4. DNA Damage Response (DDR) Target Screening & Profiling Services
  5. WRN Screening & Profiling Service

WRN Screening & Profiling Service

OverviewService ProfilingCapabilitiesHighlightsContact UsFAQ

Overview

WRN, a RecQ helicase family member, has emerged as a highly context-dependent therapeutic target. Unlike broad-acting DDR regulators, WRN inhibition induces synthetic lethality specifically in MSI-H tumors while sparing MSS cells, positioning it as a promising next-generation precision oncology target. Through its dual enzymatic activities (ATP-dependent helicase and 3'–5' exonuclease), WRN coordinates replication fork progression, DNA repair, and telomere maintenance; its dysregulation not only drives genomic instability but also creates exploitable vulnerabilities in specific tumor contexts.

Building on deep expertise in DDR biology and target-driven drug discovery, Creative Biogene has established a fully integrated WRN screening and profiling platform. This system connects enzymatic characterization, cellular dependency validation, and translational modeling into a unified workflow, enabling clients to move efficiently from target hypothesis to clinically relevant drug candidates.

From Mechanism to Therapeutic Opportunity

WRN's biological significance lies in its multifunctional architecture. Its helicase domain unwinds complex DNA structures such as G-quadruplexes and replication intermediates, while its exonuclease domain processes DNA ends during repair. This coordinated activity is particularly critical in resolving replication stress and maintaining genome integrity in rapidly proliferating tumor cells.

Figure 1. WRN helicase resolves replication-associated DNA secondary structures and enables fork restart. (Datta A, et al., 2020)

Recent studies have demonstrated that MSI-H cancers are critically dependent on WRN function. Loss of WRN in these models leads to catastrophic DNA damage, chromosome fragmentation, and cell death—defining a robust synthetic lethal interaction. At the same time, emerging evidence suggests that WRN inhibition may synergize with PARP inhibitors and other DDR-targeted agents, opening new avenues for combination therapy development.

However, WRN-targeted drug discovery presents unique challenges:

  • Coordinating helicase and exonuclease activity measurements within a single framework
  • Translating biochemical inhibition into cellular synthetic lethality
  • Ensuring specificity across the RecQ helicase family (e.g., BLM, RECQL1)
  • Establishing clinically relevant MSI and replication stress models

Creative Biogene addresses these challenges through a mechanism-driven, multi-layered screening strategy.

Integrated Technology Platform for WRN Drug Discovery

Unlike conventional CRO services that focus on a single enzymatic readout, our platform is designed to capture the full functional spectrum of WRN activity and its biological consequences. The workflow progresses from biochemical activity to pathway-level validation and ultimately to translational relevance.

Target & Genetic Coverage for WRN Screening

Our WRN platform supports not only direct targeting of WRN itself but also validation across relevant genetic contexts that drive synthetic lethality and combination strategies.

Dual Enzymatic Activity Profiling

WRN is one of the few DDR proteins with both helicase and exonuclease activities. Our platform quantitatively assesses both, ensuring a comprehensive characterization of candidate inhibitors.

We implement:

  • DNA unwinding assays using fluorescence-based helicase substrates to quantify strand separation kinetics
  • ATPase activity measurements to evaluate energy-dependent helicase function
  • Exonuclease activity assays for 3'–5' DNA processing capability
  • Coordinated helicase–exonuclease coupling analysis to assess functional integration

This dual-activity profiling enables early identification of mechanism-specific inhibitors and avoids the common pitfall of partial or misleading activity readouts.

Synthetic Lethality and Dependency Modeling

The therapeutic value of WRN lies in its context-specific essentiality. To translate biochemical findings into actionable insights, we have developed robust cellular systems that capture WRN dependency.

Our models include MSI-H tumor cell lines, CRISPR-engineered WRN knockout/knockdown systems, and isogenic MSS controls. Within these systems, we evaluate:

  • Cell viability and clonogenic survival under WRN inhibition
  • DNA damage accumulation (γH2AX, 53BP1 foci)
  • Replication stress markers and fork collapse
  • Chromosomal instability and mitotic defects

These readouts define the true synthetic lethal window and enable accurate prediction of therapeutic potential.

Drug Screening Workflow

WRN inhibitor discovery requires a tightly integrated workflow bridging enzymatic screening, cellular validation, and mechanistic interpretation.

High-Throughput Screening (HTS)

Our automated platforms support 96- and 384-well formats, enabling rapid screening of compound libraries against helicase and ATPase activities. Multi-readout designs ensure simultaneous capture of different functional dimensions.

Hit Validation and Mechanistic Profiling

Primary hits are advanced through a rigorous validation cascade, including IC50 determination, binding affinity measurement (SPR/BLI), and selectivity profiling across RecQ family members. Mechanistic assays further define whether compounds inhibit helicase activity, disrupt ATP binding, or interfere with DNA substrate interaction.

Cellular Translation

Validated hits are tested in MSI-H models to confirm synthetic lethality and to distinguish on-target activity from non-specific cytotoxicity.

Combination Strategy Evaluation

Given the strong rationale for combinatorial DDR targeting, we systematically assess WRN inhibitors in combination with PARP inhibitors, ATR inhibitors, and DNA-damaging agents. Synergy analysis identifies optimal therapeutic pairings and informs clinical strategy design.

Laboratory Capabilities and Quality System

All WRN-related studies are conducted within Creative Biogene's integrated research infrastructure, designed to meet the demands of modern drug discovery programs.

Our capabilities include high-throughput screening systems, advanced biophysical interaction platforms (SPR, BLI), high-content imaging for cellular phenotyping, and precision gene editing technologies for model development. Protein production, assay development, and cellular validation are performed under standardized workflows aligned with ISO-oriented quality management principles, ensuring reproducibility and data integrity across projects.

Why Creative Biogene

Creative Biogene's WRN platform is built to bridge the gap between mechanistic biology and drug development execution. Rather than delivering isolated assay results, we provide an integrated decision-support framework that connects enzymatic data, cellular phenotypes, and therapeutic implications.

Our approach emphasizes:

  • Full-spectrum WRN activity coverage (helicase, ATPase, exonuclease)
  • Context-driven validation in MSI and replication stress models
  • Mechanism-based classification of candidate compounds
  • Seamless transition from screening to translational strategy

This enables clients to prioritize the right compounds, avoid late-stage attrition, and accelerate progression toward clinical development.

Start Your WRN-Driven Drug Discovery Program

As DDR-targeted therapies evolve beyond PARP inhibition, WRN represents a new class of precision vulnerabilities—defined not by universal essentiality, but by context-specific dependency.

Creative Biogene supports this transition by transforming WRN biology into actionable drug discovery strategies. Whether your program is focused on early target validation, inhibitor screening, or combination therapy development, our platform can be tailored to deliver the depth, speed, and clarity required for confident decision-making.

FAQ

How do I determine whether WRN is a relevant target for my project?

WRN dependency is most strongly associated with MSI-H tumors. If your project involves colorectal, endometrial, or other MSI-associated cancers, WRN is a high-priority target. For projects without a defined MSI status, we recommend initial stratification using MSI profiling and functional dependency screening to assess WRN sensitivity.

Do I need to evaluate both helicase and exonuclease activities?

Yes, in most cases. While helicase activity is the primary focus of many inhibitors, exonuclease function contributes to WRN's biological role. Evaluating both ensures a comprehensive understanding of the compound mechanism and avoids incomplete characterization.

How is specificity ensured across the RecQ helicase family?

We incorporate selectivity profiling against related helicases such as BLM and RECQL1. This is critical to minimize off-target effects and improve downstream safety and efficacy profiles.

Can WRN screening be combined with PARP inhibitor studies?

Absolutely. WRN and PARP represent complementary DDR targets. Our platform supports combination screening and synergy analysis, particularly relevant for overcoming resistance and expanding therapeutic windows.

References:

  1. Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019 Apr;568(7753):551–556.
  2. Aggarwal M, Sommers JA, Shoemaker RH, et al. WRN as a novel target of synthetic lethality: current advances and future perspectives. J Med Chem. 2016 Mar 24;59(6):5223–5231.
  3. Wang Y, Li J, Chen J, Zhang H, et al. Targeting Werner helicase with synthetic lethality in microsatellite unstable cancers. Mol Oncol. 2022 Apr;16(8):1234–1245.
  4. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24.
  5. Datta A, Dhar S, Awate S, et al. Synthetic Lethal Interactions of RECQ Helicases. Trends Cancer. 2021 Feb;7(2):146-161.
Quick Inquiry
Products

Transfected Stable Cell Lines

Premade Virus Particles

Laboratory Equipment

RNA Interference Products

Cell Lysate

Clones

Enzymes

Kits

Aptamers

Services

Stable Cell Line Generation

Target-based Drug Discovery Service

Custom Libraries Construction Service

Microbe Genome Editing Service

Biosafety Testing Service

Nucleotides Service

MicroRNA Service

RNAi Service

Custom Viral Service

Platforms

CRISPR/Cas9 PlatformCB

QvirusTM Platform

IntegrateRNA Platform

Microbiology Platform

Zebrafish Platform

Get in Touch

Tel

Fax

Email

USA

Germany

Copyright © 2026 Creative Biogene. All rights reserved.

Privacy Policy | Cookie Policy